To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients

CompletedOBSERVATIONAL
Enrollment

510

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

June 14, 2021

Study Completion Date

June 14, 2021

Conditions
Prostate Cancer
Interventions
DRUG

LHRH analogues

3-or 6-month formulations

Trial Locations (27)

15006

Hospital A Coruña, A Coruña

15405

Hospital Arquitecto Marcide, Ferrol

15706

Hospital Clínico de Santiago, Santiago de Compostela

28006

Hospital de la Princesa, Madrid

28046

Hospital Univ. La Paz, Madrid

28500

Hospital del Sureste, Arganda

28703

Hospital Univ. Infanta Sofía, Madrid

28850

Hospital de Torrejón, Madrid

28905

Hospital Univ. de Getafe, Getafe

28933

Hospital Rey Juan Carlos, Madrid

30120

Hospital Uni. Virgen de la Arrixaca, Murcia

30202

Hospital Gral. Univ. Santa Lucía, Cartagena

31008

Hospital Virgen del Camino, Pamplona

33394

Hospital de Cabueñes, Gijón

33401

Hospital San Agustín, Avilés

34004

Hospital Comarcal Santiago Apóstol, Miranda de Ebro

35010

Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria

36312

Hospital Ntra. Señora del Cristal, Ourense

Hospital de Montecelo, Pontevedra

Hospital Álvaro Cunqueiro, Vigo

37007

Hospital de León, León

Hospital Univ. de Salamanca, Salamanca

38320

Hospital Universitario de Canarias, Santa Cruz de Tenerife

47005

Hospital Clínico de Valladolid, Valladolid

48902

Hospital de Txagorritxu, Barakaldo

Hospital de Basurto, Bilbao

08003

Hospital Son Llàtzer, Palma

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT03017313 - To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients | Biotech Hunter | Biotech Hunter